SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
530Perhaps BIIB will just take over EXEL. :-)Ian@SI-6/30/2010
529Scangos leaves to head up Biogen and EXEL stock does . . . nothing, wtuck-6/30/2010
528I'd think taking Bristol's $17M would prohibit them from suing :) rkrw-6/23/2010
527Was BMY's objective to delay EXEL's compound while they advanced theirs?Ian@SI-6/23/2010
526Sally, in comment #4, has the right take here: pipeline.corante.com Cheers, Ttuck-6/23/2010
525BMY mkt cap is 44B; Sales almost 20B. EXEL mkt cap is 400M; Sales about 150M. Ian@SI16/22/2010
524EXEL; Bristol Paid $240 m for the rights in 2008 and paying xtra 17 m now to getmlkr16/22/2010
523So do you think their market cap will go up by $17M when the market opens? :(Ian@SI-6/21/2010
522Turns out it is good news, Bristol gives Exel $17M to take it back :) Bristolrkrw-6/21/2010
521We know they've had side effect issues and dose reductions with 184 for Gliorkrw-6/19/2010
520Very late PR on a Friday long after market closes and almost summer... But the Ian@SI-6/18/2010
519XL 184 at ASCO: "Long-Term Phase 1 Results in a Cohort of Medullary Thyroituck-5/20/2010
518seekingalpha.com Transcripts of conf call on earnings/product developmentNeil H-5/12/2010
517Transcript already from seekingalpha: seekingalpha.com Cheers, Tucktuck-3/9/2010
516From Derek: I'm hearing from more than one source that Exelixis has laid offmopgcw-3/9/2010
515I looked at the slides from the recent bio ceo confab. Things seem to still statuck-2/23/2010
514Things seem awfully quiet in Exelixis-land. By now, they were supposed to be sttuck-2/23/2010
513Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR24540mopgcw-11/18/2009
512Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR24540Neil H-11/17/2009
511More ASCO related news out of EXEL <b>Exelixis Reports Encouraging Phase Ian@SI-5/30/2009
510Perhaps SNY could have just started bottling DHA. ;-) Public release date: 29-Ian@SI-5/29/2009
509my thinking is along 2 major themes here: 1. on a macro basis, the recent markemopgcw-5/28/2009
508George, Any particular rationale? Just because it's a long time between Ian@SI-5/28/2009
507fwiw, I took all my chips off the table with this one. mopgcw-5/28/2009
506excerpt from WSJ story at: online.wsj.com ... Exelixis has thrived by negotiatIan@SI-5/28/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News